Protalix BioTherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Protalix BioTherapeutics has a total shareholder equity of $29.8M and total debt of $20.4M, which brings its debt-to-equity ratio to 68.6%. Its total assets and total liabilities are $89.8M and $60.0M respectively. Protalix BioTherapeutics's EBIT is $8.1M making its interest coverage ratio 6.2. It has cash and short-term investments of $48.5M.
Key information
68.6%
Debt to equity ratio
US$20.42m
Debt
Interest coverage ratio | 6.2x |
Cash | US$48.49m |
Equity | US$29.79m |
Total liabilities | US$60.04m |
Total assets | US$89.83m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PBDA's short term assets ($75.4M) exceed its short term liabilities ($54.8M).
Long Term Liabilities: PBDA's short term assets ($75.4M) exceed its long term liabilities ($5.2M).
Debt to Equity History and Analysis
Debt Level: PBDA has more cash than its total debt.
Reducing Debt: PBDA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: PBDA's debt is well covered by operating cash flow (28.7%).
Interest Coverage: PBDA's interest payments on its debt are well covered by EBIT (6.2x coverage).